ClinicalTrials.gg
RecruitingNCT07896109Updated Nov 10, 2026

A Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and Participants With Type 2 Diabetes

A Phase 1 interventional study of NNC9836-0001 and Placebo (NaCl) in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Recruiting at 1 site in Germany. Open to participants aged 25 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

How we know

Updated Nov 10, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
25 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S — 27 open to participants now, 31 under way, 11 of them phase 3. Diabetes Mellitus, Type 2 · Novo Nordisk A/S.

Planned enrollment
259th of 430
121 · median 209
Started
2026
with 24 others
Phase 1
130 of 645
6 open now
Primary completion
2028-07
later than 20 of 30 live
Registered
639th of 645
by date

Among the 645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 259th largest by planned enrollment of the 430 interventional ones that give a count, is one of 25 that started in 2026, is one of 130 in phase 1, reaches primary completion later than 20 of the 30 other live ones, and was the 639th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

27 of the 645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

21 more — sign in →

By country, each count listing its studies:

All 27 open studies →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 373 (42%) set no upper age limit and 384 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 25 Years to 69 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, or all of them as a file.
02

Study summary

The purpose of this clinical study is to determine if the study medicine NNC9836-0001 is safe and tolerable in healthy participants with overweight or obesity or who have type 2 diabetes (T2D). Participants will either get the study medicine NNC9836-0001 or placebo. Which treatment participants get is decided by chance. NNC9836-0001 is a new medicine aimed to treat type 2 diabetes.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
25 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All participants:

  • obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
  • Male or female (sex assigned at birth, inclusive of all gender identities).

Metabolically healthy participants with overweight or mild obesity:

  • Age 25 to 59 years (both inclusive) at the time of signing the informed consent.
  • (BMI) 25 to 34.9 kilogram per square meter (kg/m\^2) (both inclusive) at screening.
  • Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, (ECG), and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Participants with type 2 diabetes:

  • Age at the time of signing the informed consent: Age 25 to 69 years (both inclusive)
  • BMI at screening: BMI 27 to 39.9 kg/m\^2 (both inclusive)
  • Diagnosed with T2D greater than equal to (≥) 180 days before screening.
  • Concomitant medications before screening: Stable (as judged by the investigator) with daily dose(s) on monotherapy (metformin, sodium-glucose cotransporter 2 inhibitors (SGLT2i), or dipeptidyl peptidase-4 inhibitor (DPP4i) or dual therapy (metformin + SGLT2i or metformin + DPP4i)) ≥90 days before screening. or; Stable weight and stable doses of glucagon-like peptide-1 receptor agonists (GLP-1 RA) with no further titration (as judged by the investigator). GLP-1 RA ≥180 days before screening combined with daily dose(s) of either metformin or SGLT2i or dual therapy (metformin + SGLT2i)) ≥90 days before screening.
  • Background pharmacotherapy for all MAD cohort T2D participants should be on stable therapy for ≥90 days before screening with no initiation, discontinuation, or dose changes.
  • Considered to be generally healthy as judged by the investigator except for T2D-associated mild conditions under stable treatment.

Exclusion criteria

Exclusion Criteria:

All participants:

  • Known or suspected to study intervention(s) or related products.
  • Previous dose administration in this study.
  • Participation (i.e., signed and dosed with medicinal product (IMP)) in any other interventional clinical study within 30 days or 5 times the half-life of the drug, whichever is longest, before screening.
  • Any disorder, which in the investigator's opinion might jeopardise participants safety or compliance with the protocol.
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using adequate method.
  • Minimal to mild hepatic impairment, defined as (ALT) values greater than (>)1.5 × (ULN), aspartate aminotransferase (AST) values >1.5 × ULN, or total >ULN + 20 percent (%) (except in case of Gilbert's disease, as reported by participant or in medical records) at screening.

Metabolically healthy participants with overweight or mild obesity:

  • Supine blood pressure outside the range of 90-139 millimetres of mercury (mmHg) for systolic or 50-89 mmHg for diastolic at screening. To consider re-assessment of vital signs in case white-coat hypertension is known or suspected.
  • Heart rate outside the range of 45-89 beats per minute (bpm) at screening.
  • Unwilling or unable to refrain from use of nonprescription products within 14 days prior to start of run-in, including herbal products and nonroutine vitamins (as judged by the investigator), except the occasional use of over the counter (OTC) acetaminophen or non-steroidal anti-inflammatory drugs (NSAIDs) at their labelled doses for mild pain.
  • Recent (\<90 days) or planned major change in diet, use of weight-lowering medication, regularly extended fasting periods, or dietary habits that, per investigator's judgment, may interfere with the conduct of the study.

Participants with type 2 diabetes:

  • Any disorder which in the investigator's opinion might jeopardise participant safety or compliance with the protocol. This does not apply for T2D-associated mild conditions under stable treatment.
  • Supine blood pressure outside the range of 90-159 mmHg for systolic or 50-99 mmHg for diastolic at screening. This exclusion criterion also pertains to participants being on antihypertensive treatment. To consider re-assessment of vital signs in case white-coat hypertension is known or suspected.
  • Heart rate outside the range of 50-99 bpm at screening.
  • Unwilling or unable to check self-monitored plasma glucose (SMPG) and unwilling to treat hypoglycaemia per instructions.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
121 participants (estimated)

Study arms

  • Experimental
    NNC9836-0001

    Participants will receive NNC9836-0001 subcutaneously.

    Drug: NNC9836-0001

  • Placebo comparator
    Placebo

    Participants will receive placebo subcutaneously.

    Drug: Placebo (NaCl)

Interventions

  • DrugNNC9836-0001

    NNC9836-0001 will be administered subcutaneously.

  • DrugPlacebo (NaCl)

    Placebo (NaCl) will be administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. Single ascending dose (SAD): Number of Treatment emergent adverse events (TEAEs)

    Measured as events.

    Time frame: From dosing (day 1) until week 26

  2. Multiple ascending dose (MAD): Number of TEAEs

    Measured as events.

    Time frame: From dosing (day 1) to week 34

Secondary outcomes

  1. SAD: Area under the curve (AUC)0-last, standard deviation (SD): The area under the NNC9836-0001 plasma concentration-time curve from time zero to last measurable concentration after a single dose

    Measured as hours\*nanograms per milliliter (h\*ng/ml).

    Time frame: From predose day 1 to day 57

  2. SAD:Cmax,SD: The maximum observed NNC9836-0001 plasma concentration after a single dose

    Measured as nanograms per milliliter (ng/ml).

    Time frame: From predose day 1 to day 57

  3. MAD: AUC0-28d,MD: The area under the NNC9836-0001 plasma concentration-time curve after multiple doses

    Measured as hour\*ng/mL.

    Time frame: From predose day 29 to day 57

  4. MAD: Cmax,MD: The maximum observed NNC9836-0001 plasma concentration after multiple doses

    Measured as ng/mL.

    Time frame: From predose day 29 to day 57

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jul 2028, 21 months after the start.

Of 454 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's planned 21 months is above that.

Counting every sponsor, half of 517 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2026
First posted
Oct 26, 2026
StartActual
Oct 22, 2026
Primary completionEst.
Jul 26, 2028
CompletionEst.
Jul 26, 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 10, 2026
Sites
Profil Institut für Stoffwechselforschung GmbH is now Recruiting
Nov 10, 2026
Start date
Oct 21, 2026→Oct 22, 2026 (actual)
Nov 10, 2026
Registered
First appeared on the registry
Oct 26, 2026
Show all 2 updates
  1. Nov 10, 2026
    Not yet recruiting→Recruiting
    Profil Institut für Stoffwechselforschung GmbH is now Recruiting
    Start date Oct 21, 2026→Oct 22, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 26, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07896109
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Oct 26, 2026
Start date
Oct 22, 2026
Primary completion
Jul 26, 2028 (estimated)
Completion
Jul 26, 2028 (estimated)
Last update
Nov 10, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency dept. 2834
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion